Investor Insight

E-Power Resources offers investors high-grade exposure to the rapidly expanding flake graphite sector through one of Québec’s most promising districts. With a strategic land position, near-surface discoveries, and a leadership team experienced in exploration and capital markets, E-Power is positioned to help supply North America’s critical battery materials chain.

Overview

E-Power Resources (CSE:EPR) is a Montréal-based company focused on advancing its flagship Tetepisca graphite property in Québec’s North Shore region. The company’s mission is to delineate and develop a high-grade, near-surface flake-graphite resource capable of supplying future North American battery-anode demand.

Since entering the Tetepisca district in 2019, E-Power has systematically advanced its project from regional geophysics to mapping, sampling, drilling and metallurgical testing. This disciplined exploration pipeline has confirmed the presence of district-scale, high-purity graphite mineralization within the same geological sequence that hosts neighboring deposits such as Focus Graphite’s Lac Tetepisca and Nouveau Monde Graphite’s Uatnan, which together hold more than 120 million tons (Mt) measured + indicated at approximately 14 percent Cg.

Graphite demand is accelerating globally as electric-vehicle production and energy-storage capacity expand. Québec’s hydroelectric grid, pro-mining policy environment, and rapidly developing anode-manufacturing infrastructure make it a world-class jurisdiction for low-carbon graphite development. Within this setting, E-Power’s land position, grade profile and technical results uniquely position the company to become a core participant in Canada’s graphite-to-battery supply chain.

Company Highlights

• Flagship project in Québec’s premier graphite district: 100-percent-owned Tetepisca Property, 234 contiguous claims covering ≈ 12,840 ha, the largest land position in the district
• Exceptional grades: 2025 surface sampling returned up to 68.7 percent Cg (carbon in graphite form) at the Graphi-Centre target, among the highest reported globally
• High-purity metallurgy: 2024 bulk sampling produced concentrates grading up to 96.4 percent Cg, validating commercial potential.
• Strategic infrastructure advantage: ~220 km from Baie-Comeau and within trucking distance of a planned 200,000 tons per year (tpy) graphite-anode facility, anchoring Québec’s battery-materials hub.
• Surging Market Demand: With global battery production accelerating, the graphite market is forecast to soar, positioning E-Power to benefit from one of the most dynamic growth trends in the energy materials sector.
• Led by Experience: Backed by a strong, technically skilled management team, E-Power is strategically positioned to advance North American graphite independence and capture growing demand in the energy transition economy.

Key Project

Tetepisca Graphite Project

The Tetepisca graphite property is approximately 220 km north of Baie-Comeau, covering 234 contiguous claims (~12,840 ha) in the heart of the Tetepisca Graphite District (TGD). The property is 100-percent-owned by E-Power and hosts the same graphitic metasedimentary units that define the district’s producing and feasibility-stage assets.

District-Scale Opportunity

The TGD is an emerging flake-graphite camp that now hosts more than 120 Mt of measured and indicated resources averaging ~14 percent Cg across nearby projects such as Nouveau Monde Graphite’s Uatnan and Focus Graphite’s Lac Tetepisca deposits.

E-Power controls the largest contiguous land position in the district, strategically covering the same graphitic metasedimentary horizons that host these deposits. The district’s proximity to the planned 200,000 tpy graphite-anode facility in Baie-Comeau creates a unique alignment of resource, infrastructure and processing capability, positioning E-Power as a potential key upstream feed source for Québec’s integrated graphite-to-anode supply chain.

2024–2025 Exploration Results

E-Power’s work since 2021 has validated the property’s high-grade, near-surface potential.

• The 2025 Phase 1 program returned grab samples up to 68.7 percent Cg at the Graphi-Centre target, one of the highest surface graphite grades reported globally.
• New discoveries on the northern claim block (N3 and N4 targets) yielded multiple samples exceeding 20 percent Cg, extending graphite mineralization across more than 330 meters of strike within continuous conductive trends.
• The Syndicate Trend, a 12 km linear conductor in the southwest, produced a new showing with grades of 54.7 percent Cg within a broader corridor that includes a historical drill intercept of 12.74 percent Cg over 9.55 meters.
• Metallurgical test work from 2024 bulk sampling confirmed high-purity concentrates of up to 96.4 percent Cg, with additional mineralogy and flake-size distribution studies underway to define commercial product potential.

E-Power’s 2025–2026 work program will focus on advancing the Tetepisca property toward an initial resource estimate. Key activities include expanded fieldwork and metallurgical testing at the Graphi-Centre, Captain Cosmos and Syndicate showings; follow-up ground and drone-borne geophysical surveys to refine drill targets; and a focused drilling campaign designed to define near-surface, high-grade graphite zones. In parallel, the company is initiating early environmental baseline and access studies to support future development and potential partnerships within Québec’s growing graphite-to-anode supply chain.

Management Team

Jean-Michel Gauthier – Chief Executive Officer

Jean-Michel Gauthier contributes significant expertise in capital markets, corporate development and strategic positioning within the resource sector. His focus will be on ensuring the optimal deployment of capital and maximizing the inherent value of the Tetepisca Project as it advances through key de-risking stages.

Mark Billings – Chairman of the Board

Mark Billings is a highly respected finance professional in the Canadian resource sector, bringing extensive investment banking and corporate finance experience. His prior roles, including VP corporate finance at Desjardins Securities, provide a crucial foundation for guiding E-Power’s capital formation and strategic financing plans necessary for the Tetepisca Project’s development phases.

Jamie Lavigne – Chief Operating Officer

Jamie Lavigne is a professional economic geologist with over 30 years of experience in exploration and mine development. He has worked with major Canadian and Australian mining companies and several junior explorers and operates his own consulting firm. Lavigne holds a B.Sc. from Memorial University and an MSc. from the University of Ottawa. He is a member of L’Ordre des Géologues du Québec and the Northwest Territories and Nunavut Association of Professional Engineers and Geoscientists.

Paul Haber – Chief Financial Officer and Corporate Secretary

Paul Haber brings over 20 years of experience in corporate finance and capital markets. He has served as CFO, board member, and audit chair for numerous public and private companies, including XTM (CSE:PAID), South American Silver (TSX:SAC), and Migao Corporation (TSX:MGO). A CPA and CA, Haber began his career at Coopers & Lybrand and holds an Honours B.A. in Management from the University of Toronto. He also holds a Chartered Director designation from the DeGroote School of Business and the Conference Board of Canada.

Christian Falk – Advisory Board Member

1. Avidity Biosciences (NASDAQ:RNA)

Year-over-year gain: 143.8 percent
Market cap: US$10.87 billion
Share price: US$72.14

Avidity Bioscience is a biopharma firm developing a new form of RNA therapy called antibody oligonucleotide conjugates (AOC) that target the genes causing rare muscle diseases.

Through its proprietary AOC platform, Avidity developed programs for three rare muscle diseases: AOC 1001 for myotonic dystrophy type 1, AOC 1044 for Duchenne muscular dystrophy and AOC 1020 for facioscapulohumeral muscular dystrophy. The company is also working to expand its pipeline into cardiology and immunology.

In October 2025, Avidity entered into a definitive agreement to be acquired by Novartis (NYSE:NVS), which will include the company’s late-stage neuromuscular programs (AOC 1001, 1020, 1044) and the AOC platform, for US$12 billion.

Avidity’s early-stage precision cardiology programs will spin off into a new public company prior to closing in H1 2026. The spin-off will also have rights to use and develop the AOC platform for cardiology applications.

2. Wave Life Sciences (NASDAQ:WVE)

Year-over-year gain: 36.52 percent
Market cap: US$3.13 billion
Share price: US$17.12

Wave Life Sciences is another clinical-stage firm focused on unlocking insights from human genetics to deliver RNA-based medicines. The company’s PRISM platform is targeting both rare and prevalent disorders. Its pipeline includes clinical programs for Duchenne muscular dystrophy, alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program for WVE-007 in obesity.

Wave Life Sciences advanced its PRISM RNA platform across multiple programs in 2025. It is also performing a Phase 1 trial testing its WVE-007 obesity candidate, which is an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design.

In December, the company reported positive interim data from the WVE-007 trial, which showed that a single dose resulted in sustained Activin E reduction, supporting infrequent dosing. Target engagement updates and body composition readouts are planned for Q1 2026.

3. UniQure (NASDAQ:QURE)

Year-over-year gain: 33.15 percent
Market cap: US$1.47 billion
Share price: US$23.86

UniQure is a gene therapy company focused on patients with severe medical needs. In November 2022, the US Food and Drug Administration (FDA) approved the company’s gene therapy Hemgenix (etranacogene dezaparvovec), which is the world’s first gene therapy for hemophilia B.

Today, uniQure’s proprietary gene therapy pipeline includes treatments for patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS and Fabry disease.

Its gene therapy pipeline advanced in 2025, with positive Phase I/II topline data for Huntington’s disease candidate AMT-130 showing 75 percent slowing of disease progression at three years via cUHDRS, alongside 60 percent functional capacity preservation.

While data from the Phase I/II study led the FDA to grant AMT-130 breakthrough therapy designation in April, in December the agency told UniQure it believes the data may not be adequate to support a pre-biologics license application under the accelerated approval pathway. The company is pursuing a follow-up meeting.

4. Stoke Therapeutics (NASDAQ:STOK)

Year-over-year gain: 186.96 percent
Market cap: US$1.81 billion
Share price: US$31.74

Stoke Therapeutics is another biotech company with a focus on developing RNA medicine. With its proprietary research platform TANGO, which stands for targeted augmentation of nuclear gene output, the company is developing antisense oligonucleotides to selectively restore protein levels.

Stoke’s first product candidate, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe form of genetic epilepsy. The company is also developing STK-002 for the treatment of autosomal dominant optic atrophy, an inherited optic nerve disorder.

Both candidates advanced in 2025, with STK-001 enrolling patients in Phase 3 after positive long-term data showed seizure reductions and cognitive gains. Likewise, STK-002’s clinical development program is being informed by results, presented in October, of a Phase 1 two year natural history study on the disease progression of autosomal dominant optic atrophy.

Copper outlook for 2026

Market watchers expect many of the forces that drove copper through 2025 to persist.

Supply constraints are expected to remain acute this year as aging mines and capacity shortfalls weigh on availability. New projects such as Arizona Sonoran Copper Company’s (TSX:ASCU,OTCQX:ASCUF) Cactus project and the long‑anticipated Resolution mine in the US are still years from significant output.

Copper demand is projected to grow as the global energy transition accelerates.

“A huge amount of this tightness has to do with US tariff concerns,” she said.

China, the world’s largest copper consumer, is also shaping the outlook. Despite weakness in its property sector, the country posted economic growth and is expected to prioritize copper‑intensive sectors under its new five year plan.

Longer‑term projections from industry groups suggest structural demand growth will outpace supply additions.

A UN report estimates that copper demand could rise 40 percent by 2040, requiring substantial investment and new mines just to keep pace. Likewise, Wood Mackenzie forecasts that copper demand will increase 24 percent by 2035, while the International Copper Study Group predicts a refined copper deficit of 150,000 metric tons in 2026 alone.

1. Stria Lithium (TSXV:SRA)

Year-to-date gain: 708.33 percent
Market cap: C$19.11 million
Share price: C$0.48

Stria Lithium is a Canadian exploration company focused on developing domestic lithium resources to support the growing demand for electric vehicles and lithium-ion batteries. The company’s flagship Pontax Central lithium project spans 36 square kilometers in the Eeyou Istchee James Bay region of Québec, Canada.

Cygnus Metals (TSXV:CYG,ASX:CY5,OTCQB:CYGGF) has an earn-in agreement with Stria to earn up to a 70 percent interest in Pontax Central. Cygnus completed the first stage in July 2023, acquiring a 51 percent interest by investing C$4 million in exploration and issuing over 9 million shares to Stria.

In May 2025, Stria and Cygnus agreed to extend the second stage of Cygnus’s earn-in agreement on the Pontax Central lithium project by 24 months. The second stage involves a further C$2 million in exploration spending and C$3 million in a cash payment.

Through its joint venture with Cygnus, Stria has outlined a JORC-compliant maiden inferred resource for Pontax Central of 10.1 million metric tons grading 1.04 percent lithium oxide.

In March, Stria closed a non-brokered private placement for C$650,000. The funds will be used in part for the evaluation of new mineral opportunities, according to the company.

Shares of Stria registered a year-to-date high of C$0.50 on December 30, 2025, coinciding with lithium carbonate prices rising to a near 24 month high.

2. Consolidated Lithium Metals (TSXV:CLM)

Year-to-date gain: 350 percent
Market cap: C$20.51 million
Share price: C$0.045

Consolidated Lithium Metals is focused on acquiring, developing and advancing lithium projects in Québec. Its properties — Vallée, Baillargé, Preissac-LaCorne and Duval — are located within the spodumene-rich La Corne Batholith area, near the restarted North American Lithium mine, a key area in Canada’s growing lithium sector.

Consolidated Lithium started the year with a C$300 million private placement earmarked for working capital and general corporate purposes.

In July, the company commenced a summer exploration program at the Preissac project, excavating a 100 by 30 meter trench in an area with a known lithium soil anomaly, uncovering an 18 meter wide pegmatite body at surface.

At the end of August, Consolidated Lithium signed a non-binding letter of intent with SOQUEM, a subsidiary of Investissement Québec, to acquire an option to earn up to an 80 percent interest in the Kwyjibo rare earths project.

The project is located roughly 125 kilometers northeast of Sept-Îles in Québec’s Côte-Nord region.

Under the deal, which was finalized in November, Consolidated Lithium will become operator of the project and can earn an initial 60 percent stake over five years through a combined C$23.15 million in cash payments, share issuances and project expenditures.

A significant portion of those funds will be invested in advancing Kwyjibo through stages including negotiating and finalizing an agreement with the Innu of Uashat mak Mani-Utenam, a metallurgical study and environmental permitting.

Upon completion, the partners will form a joint venture, and Consolidated will have the option to increase its interest to 80 percent by investing C$22 million over a further three years.

An uptick in lithium prices in October helped Consolidated shares rally to a year-to-date high of C$0.06 several times between October 22 and November 3.

3. Lithium South Development (TSXV:LIS)

Year-to-date gain: 330 percent
Market cap: C$48.76 million
Share price: C$0.43

Canada-based Lithium South Development currently owns 100 percent of the HMN lithium project in Argentina’s Salta and Catamarca provinces, situated in the heart of the lithium-rich Hombre Muerto Salar.

The project lies adjacent to South Korean company POSCO Holdings’ (NYSE:PKX,KRX:005490) billion-dollar lithium development to the east.

Exploration has defined a resource of 1.58 million metric tons of lithium carbonate equivalent (LCE) at an average grade of 736 milligrams per liter lithium, with the majority in the measured category. A preliminary economic assessment outlines the potential for a 15,600 metric ton per year lithium carbonate operation.

In January 2024, Lithium South and POSCO signed an agreement to jointly develop the HMN lithium project. Under the deal, the companies will share production 50/50 from the Norma Edith and Viamonte blocks in Salta and Catamarca, resolving overlapping claims.

As for 2025, in June Lithium South’s shares tripled to C$0.30 after it received positive news regarding its environmental impact assessment.

Lithium South shared a huge update in July that changed its trajectory; the company received a non-binding cash offer of US$62 million from POSCO to purchase its lithium portfolio, including the HMN project.

POSCO would acquire Lithium South’s wholly owned subsidiary NRG Metals Argentina, which holds the HMN project and all of Lithium South’s other concessions, namely the Sophia I–III and Hydra X–XI claims.

The 60 day due diligence period concluded in late September, and on November 12, Lithium South announced a share purchase agreement to sell its Argentinian lithium portfolio to POSCO Argentina for US$65 million.

Company shares climbed to C$0.44 the next day, while its highest close of the year, C$0.45, came on December 24.

Lithium South officially signed the deal on December 8, with its closing subject to several approvals. Following the transaction’s completion, Lithium South plans to de-list from the TSXV and begin dissolution proceedings.

In connection with the news, the company intends to buy back all common shares at a price of C$0.505.

4. Standard Lithium (TSXV:SLI)

Year-to-date gain: 190 percent
Market cap: C$1.47 billion
Share price: C$6.15

Standard Lithium is a US-focused lithium development company advancing a portfolio of high-grade lithium brine projects with an emphasis on sustainability and commercial-scale production.

The company employs a fully integrated direct lithium extraction process and is developing its flagship Smackover Formation assets in Arkansas and Texas, including the South West Arkansas project. The projects are a partnership with Equinor ASA, under the 55/45 joint venture subsidiary Smackover Lithium.

In April, its South West Arkansas project was one of 10 US critical minerals projects designated for fast tracking under FAST-41.

On September 3, Standard Lithium reported results of its definitive feasibility study (DFS) for the South West Arkansas project. The DFS notes an initial capacity of 22,500 metric tons per year of battery-grade lithium carbonate, with first production targeted for 2028. The study outlines an operating life of over 20 years based on average lithium concentrations of 481 milligrams per liter, supported by detailed resource and reserve modeling. The company filed the DFS on October 14.

In late October, Standard Lithium reported the unanimous approval of the Arkansas Oil and Gas Commission for the company’s Integration Application for the project’s Reynolds brine unit, which is where the initial commercial phase of production is planned.

Standard is also actively exploring additional lithium brine opportunities in East Texas through the joint venture, and in November, Smackover Lithium filed the maiden inferred resource report for the Franklin project. The report highlights 2.16 million metric tons of LCE, 15.41 million metric tons of potash and 2.64 million metric tons of bromide contained in 0.61 square kilometers of brine volume.

The resource stands at an average lithium grade of 668 milligrams per liter, including a grade of 806 milligrams per liter at the Pine Forest 1 well, which the company states is North American’s highest concentration of lithium-in-brine.

The project covers roughly 80,000 acres, with 46,000 acres leased, and is poised to become the first phase in a broader East Texas expansion. Smackover Lithium ultimately aims to produce over 100,000 metric tons of lithium chemicals annually from its Texas operations.

On October 20, Standard closed a US$130 million underwritten public offering for 29,885,057 common shares, which will fund capital expenditures at the South West Arkansas project and the Franklin project.

Standard and Equinor ended the year advancing project financing for its South West Arkansas project, targeting up to US$1.1 billion in senior secured debt. The company has received over US$1 billion in combined interest from major export credit agencies, including the US EXIM Bank and Norway’s Eksfin.

The potential funds, alongside a US$225 million grant from the US Department of Energy, would support Phase 1 construction, which has an estimated US$1.45 billion in capital expenditures, FEED and feasibility study costs, and typical financing contingencies.

After climbing steeply starting in late September, the company’s shares hit a year-to-date high of C$7.64 on October 16.

5. Q2 Metals (TSXV:QTWO)

Year-to-date gain: 144.87 percent
Market cap: C$363.79 million
Share price: C$1.97

Exploration firm Q2 Metals is exploring three lithium properties — Cisco, Mia and Stellar — in the Eeyou Istchee James Bay region of Québec, Canada. Contained within the portfolio is the Mia trend, which spans over 10 kilometers, while the Stellar lithium property comprises 77 claims and located 6 kilometers north of the Mia property.

In 2024, Q2 Metals acquired Cisco lithium property and spent the rest of the year exploring the area. The work led to Q2 acquiring a 100 percent interest in 545 additional mineral claims, tripling its land position at the Cisco lithium property.

A subsequent company update reported that metallurgical testing on drill core from its 2024 exploration work confirmed that spodumene is the primary lithium-bearing mineral within pegmatite at the project.

The company performed multiple drill campaigns in 2025, including a winter diamond drilling program. Over the course of the year, Q2 defined an exploration target and reported a series of positive results from test work and drilling at the project.

The most recent announcement, released December 3, singled out results from drill hole 44 as the ‘widest continuous spodumene pegmatite interval’ identified at the property. The hole intersected 457.4 meters of continuous mineralization with an average grade of 1.65 percent lithium oxide.

‘Drill hole 44 further showcases the Cisco project as a globally significant hard rock lithium discovery. The results to date will underpin the inaugural Mineral Resource Estimate, which we expect to announce in the first quarter of 2026, as we continue to advance Cisco,’ wrote Alicia Milne, president and CEO of Q2 Metals.

The company’s share price began climbing in late October following the news that it added Keith Phillips, CEO of Piedmont Lithium from 2017 to 2025, to its board of directors.

Propelled by the board addition and the drilling results results, shares of Q2 Metals ended 2025 on a high note, registering a year-to-date high of C$1.95 on December 30.

1. MDxHealth (NASDAQ:MDXH)

Year-on-year gain: 50.86 percent
Market cap: US$173.24 million
Share price: US$3.50

MDxHealth is a commercial-stage precision diagnostics company specializing in molecular tests for urologic cancers, particularly prostate cancer, using genomic, epigenetic and exosomal technologies. Its US headquarters and operations are located in Irvine, California.

The company offers non-invasive and tissue-based diagnostic assays that run on standard PCR platforms.

In September, MDxHealth acquired Exosome Diagnostics from Bio-Techne (NASDAQ:TECH) for US$15 million, adding the ExoDx Prostate urine test to its portfolio. The deal also includes a CLIA-certified clinical laboratory and related assets. The deal is expected to generate over US$20 million in revenue in 2026.

2. KORU Medical Systems (NASDAQ:KRMD)

Year-on-year gain: 50.13 percent
Market cap: US$269.6 million
Share price: US$5.82

KORU Medical Systems develops and manufactures medical devices and supplies in the US and internationally, with a focus on mechanical infusion products. Its Freedom Syringe Infusion System first received FDA clearance in 1994.

Based on this system, its primary products include the Freedom60 and FreedomEdge syringe infusion systems, Precision Flow Rate Tubing and High-Flo Subcutaneous Safety Needle Sets.

KORU Medical Systems submitted a 510(k) premarket notification to the FDA on December 30, 2025, seeking clearance for its FreedomEdge system to deliver Phesgo — a HER2+ breast cancer targeted biologic — subcutaneously, targeting infusion centers to cut chair time and boost efficiency.

The company stated this is part of its strategy to expand the indications of FreedomEdge to the wider oncology infusion center market.

3. Vivani Medical (NASDAQ:VANI)

Year-on-year gain: 1.71 percent
Market cap: US$86.81 million
Share price: US$1.19

Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology to treat chronic conditions like obesity and type 2 diabetes.

Headquartered in Alameda, California, Vivani focuses on GLP-1 implants that provide steady drug release over six months to improve adherence and tolerability compared to daily pills or weekly injections.

In August, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial of the NPM-115 exenatide implant, confirming safety and steady drug release for obesity treatment without major side effects.

The company plans to rapidly advance its NPM-139 semaglutide implant after it achieved preclinical results of sustained 20 percent weight loss. It is planning a Phase 1 clinical study in the first half of 2026.

European cannabis legalization and international growth

2025 brought incremental legalization or medical frameworks in multiple jurisdictions, including Czechia, Malta, Poland, Switzerland and Luxembourg, broadening the investable global footprint.

This continental momentum has directly boosted North American producers through export ramps and licensing deals, with Canadian licensed producers capturing 43 percent of Germany’s Q2 imports alone.

The country’s CanG framework and adult‑use reform, which came into effect in April 2024, have made it Europe’s most important legal market, with 2025 medical sales expected to see explosive year-on-year growth.

Investor takeaway

2025 marked a transformative year for cannabis, with regulatory breakthroughs and market maturation set against the backdrop of volatility. Trump’s execuctive order has brought new life into the sector in the US with the promise of not only banking and tax relief, but also bipartisan momentum for normalization; however, investors remain cautious.

“Everybody is waiting for it to be real and for it to be completed. Because even though we think the executive order was huge … nothing’s complete yet. Nothing’s official yet,” explained Ahrens.

Looking to 2026, he emphasized that the path forward for cannabis isn’t a straight line, but rather a series of volatile ‘waves’ tied to incremental regulatory milestones. Ahrens anticipates that while the finalization of Schedule III should trigger an initial move, it is merely the first domino; subsequent upside depends on the DoJ providing clear guidance for state-legal adult-use programs and the eventual passage of banking reform.

While he does foresee cannabis stocks uplisting to major exchanges, and Big Pharma companies beginning to make acquisitions in the space, Ahrens remains cautious about timing, noting that even with a signed order, large institutional banks will likely keep the ‘blockade’ in place until the legal ink is truly dry.

Ultimately, while 2025’s executive action has established a concrete foundation for federal reform in the US, the cannabis sector remains poised in a state of high-stakes volatility, with its full maturation dependent on official completion of milestones in 2026 and beyond.

Investor Insight

Centurion Minerals offers investors an early-stage entry point into a strategically located gold exploration company positioned within one of North America’s most prolific and active mining districts. With a restructured corporate foundation, and a highly experienced geological and corporate finance team, the company is primed for value-creating discoveries.

Overview

Centurion Minerals (TSXV:CTN) is a Canadian exploration company focused on the acquisition, exploration and development of precious metals projects in the Americas.

The company’s strategy is centered on advancing high-quality, early-stage gold assets through systematic exploration to define drill-ready targets and unlock the discovery potential inherent in its three-part claim package: the Newman, Noseworthy and Hepburn properties. Situated near major operations and new discoveries, these claims benefit from excellent infrastructure, year-round road access and proximity to proven mineralized structural corridors. Centurion intends to increase shareholder value through targeted geophysics, ground truthing and drilling programs designed to reveal new high-grade zones, as well as through potential future acquisitions of complementary gold assets across the Americas.

Backed by a leadership team with decades of exploration, geology, corporate finance and project development experience, Centurion is positioned to capitalize on strong gold market fundamentals and renewed investor interest in junior exploration companies. With a low current valuation and advancing work program, the company provides leverage to both exploration success and broader trends in the gold sector.

Company Highlights

• Highly prospective gold project in a world-class district located in the central north Abitibi greenstone belt, adjacent to major deposits and producing mines including Hecla Mining’s (NYSE:HL) Casa Berardi mine and Agnico Eagle’s (TSX:AEM) Detour Lake operations.
• Exceptional closeology advantage, with its Casa Berardi West project situated just 12 km from AMEX Exploration’s (TSXV:AMX) 1.6 Moz “Perron” discovery and along the same structural corridors that have produced multi-million-ounce deposits.
• Significant historic drilling across the three claim groups, including results up to 38 g/t gold and multiple intervals indicating gold-bearing iron formations and shear zones.
• Clear exploration strategy including historic data compilation, geophysical surveys, target generation and a planned program to define new mineralized zones.
• Experienced management and technical team with decades of experience in mineral exploration, and international corporate finance, enhances the potential of uncovering additional exploration opportunities.
• Low market capitalization and recently reactivated corporate structure, offering investors a low entry point ahead of meaningful upside catalysts.

Key Project

Casa Berardi West Gold Project

The Casa Berardi West project is Centurion’s flagship gold exploration asset, encompassing approximately 6,732 hectares across three contiguous claim groups – Newman, Noseworthy and Hepburn – located 66 km northeast of Cochrane, Ontario. The project sits along structural corridors that host some of the region’s most significant deposits, including Hecla Mining’s Casa Berardi mine (3 Moz past production, plus 4 Moz in reserves and resources), Agnico Eagle’s Detour Lake mine (15 Moz reserve, producing ~659,000 oz of gold per year ), and AMEX Exploration’s Perron discovery (1.6 Moz measured and indicated resource at 6.14 g/t gold).

Location of the three claim groups at Casa Berardi West

Geological Setting & Closeology Advantage

The project is situated within the central north Abitibi Subprovince, an Archean greenstone belt known globally for its prolific endowment of gold and base metals. The claims lie adjacent to geological features associated with multiple major deposits – iron formations, shear zones and VMS trends – creating strong analogues to high-grade gold mines such as the Musselwhite mine in Northern Ontario.

This “closeology” positioning significantly enhances the potential for Centurion’s ground to host similar mineralization.

Historic Results & Target Areas

Historic exploration across the Casa Berardi West project – spanning more than 70 RC and diamond drill holes – has already confirmed the presence of gold-bearing structures and favorable host rocks. Notably, previous work returned multiple samples above 1 g/t gold, including a standout result of 38 g/t gold, demonstrating strong mineralization potential across the claim area.

Significant historic drill results at Newman target

Across the three claim groups, drilling and geophysical surveys have identified key geological features associated with major deposits in the region, including iron formations, shear zones and sulphidized horizons. Several zones of interest remain untested or underexplored, particularly along structural trends that extend from nearby high-grade gold and VMS systems such as the Perron and Normetal areas.

These findings provide Centurion with multiple high-priority target areas for follow-up exploration, forming the foundation for its next phase of geophysical work and upcoming drill targeting.

Management Team

David Tafel – Director, President and CEO

David Tafel brings over 30 years of experience in corporate structuring, strategic planning, financing and executive management across multiple public and private resource companies. He has raised several hundred million dollars for ventures in mining, technology and life sciences, and previously managed private investment funds at Canada’s largest independent securities firm.

Jeremy Wright – Director and CFO

A seasoned financial executive with more than 20 years of experience, Jeremy Wright serves as president & CEO of Seatrend Strategy Group and has held CFO roles across numerous public companies in the resource and technology sectors. His background includes financial management, negotiations and environmental economics, supported by extensive board leadership experience.

Joseph Del Campo – Director

Joseph Del Campo has served as CFO and Interim CEO across several mining companies, including Unigold and First Nickel. With decades of corporate financial leadership and board experience, he contributes deep governance, audit and operational oversight expertise to Centurion’s board.

Mike Kilbourne – Geological Consultant

A veteran geologist with 40+ years of industry experience, Mike Kilbourne has managed over 100,000 metres of drilling across North America and Mexico, worked as a production geologist in multiple mining environments, and generated over 700 exploration targets for private and public companies.

Jamie Lavigne – Geological Consultant

Jamie Lavigne is a senior exploration geologist with more than 30 years of experience in base and precious metals. He has held senior technical roles with major mining companies and specializes in advanced exploration, resource delineation and geological modeling across global mineral belts.